Volume 48, Issue 12 pp. 2515-2524

Blood components produced from whole blood using the Atreus processing system

Stephen Thomas

Stephen Thomas

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
Martin Beard

Martin Beard

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
Margaret Garwood

Margaret Garwood

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
Martine Callaert

Martine Callaert

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
Geert van Waeg

Geert van Waeg

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
Rebecca Cardigan

Rebecca Cardigan

From the Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK; and Gambro BCT, Zaventem, Belgium.

Search for more papers by this author
First published: 05 December 2008
Citations: 16
Stephen Thomas, PhD, Components Development Laboratory, NHS Blood & Transplant, Brentwood, Essex CM15 8DP, UK; e-mail: [email protected].

Funded by Gambro BCT, Zaventem, Belgium.

Abstract

BACKGROUND: The Atreus 2C+ system (Gambro BCT) automates whole blood (WB) processing into a single device. This study compared the quality of red blood cells (RBCs), fresh-frozen plasma (FFP), and buffy coats (BCs) made from WB held with or without active cooling.

STUDY DESIGN AND METHODS: WB was collected into Atreus disposables and stored with (n = 20) or without (n = 20) active cooling for 14 to 18 hours at 22 ± 2°C before processing with the Atreus. Two RBC leukodepletion filters were assessed, and markers of RBC quality were tested to Day 42. BCs were held for 3 hours before testing, plasma was tested, and samples were frozen for coagulation analysis.

RESULTS: RBCs met UK specifications for volume, hemoglobin content (48 ± 5 g), and hematocrit (Hct). Hemolysis, adenosine triphosphate, 2,3-diphosphoglycerate, potassium, glucose, and lactate throughout storage were all within expected ranges. No differences were seen in RBC produced from WB held with or without active cooling. FFP units met UK specification for volume, total protein, cellular contamination, and coagulation factors. No differences were seen in FFP produced from WB held with or without active cooling. The Hct of BCs produced from WB held without active cooling was lower than in BCs from WB held with active cooling; no differences in activation were seen.

CONCLUSION: From these in vitro data, blood components produced using the Atreus appear suitable for clinical use, with no clinically significant difference in the quality of components from WB held at ambient temperature overnight with or without active cooling.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.